Yazar "He, X." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Gumus, M.; Kilickap, S.; Sezer, A.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.[Abstract Not Available]Öğe Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 1 histology subgroups(ELSEVIER, 2022) Sezer, A.; Kılıçkap, Saadettin; Gümüş, M; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; He, X.; Gullo, Guiseppe; Rietschel, Petra; Quek, RubenPatient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroupsÖğe Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in EMPOWER-lung 1(Elsevier Science, 2022) Sezer, Ahmet; Gümüş, Mahmut; Bondarenko, Igor N; Özgüroğlu, Mustafa; Gogishvili, Miranda; He, X.; Gullo, Guiseppe; Rietschel, Petra; Quek, Ruben GwPatient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in empower-lung 1
